Sjacobs26, In preparation for the ESMO results
Post# of 154560
(Total Views: 729)
Posted On: 05/08/2025 4:26:21 PM
Sjacobs26,
In preparation for the ESMO results that we will probably obtain, I am sharing a study that includes Kaplan-Meier curves available for metastatic triple-negative breast cancer (mTNBC) clinical trials involving approved drugs. One study reconstructs survival data for subgroups with low PD-L1 expression in advanced/metastatic TNBC using a new method/workflow (KMSubtraction) to extrapolate "missing" data for subgroups.
The studies include Atezolizumab in combination with paclitaxel as a first-line treatment and pembrolizumab on advanced/metastatic TNBC treatment with multiple chemotherapy regimens (gemcitabine- carboplatin, paclitaxel, or nab- paclitaxel) and focus on the results as they correlate to PD-L1 expression.
https://jitc.bmj.com/content/jitc/12/1/e007931.full.pdf
The number of patients in these studies are large (sometimes more than 200) and it makes it clear than survival beyond 36 months and even 27 months) is extremely rare and that, in some cases there is no difference between chemo and a regime with some of the drugs.
The utility of these Kaplan-Meier (K-M) curves is that it might allow us to make educated statistical comparisons once we have data from LL patients (of course with the caveat of a much-reduced number "at risk" in our case.)
Can't wait for us to start our trial and see the results!!!.
In preparation for the ESMO results that we will probably obtain, I am sharing a study that includes Kaplan-Meier curves available for metastatic triple-negative breast cancer (mTNBC) clinical trials involving approved drugs. One study reconstructs survival data for subgroups with low PD-L1 expression in advanced/metastatic TNBC using a new method/workflow (KMSubtraction) to extrapolate "missing" data for subgroups.
The studies include Atezolizumab in combination with paclitaxel as a first-line treatment and pembrolizumab on advanced/metastatic TNBC treatment with multiple chemotherapy regimens (gemcitabine- carboplatin, paclitaxel, or nab- paclitaxel) and focus on the results as they correlate to PD-L1 expression.
https://jitc.bmj.com/content/jitc/12/1/e007931.full.pdf
The number of patients in these studies are large (sometimes more than 200) and it makes it clear than survival beyond 36 months and even 27 months) is extremely rare and that, in some cases there is no difference between chemo and a regime with some of the drugs.
The utility of these Kaplan-Meier (K-M) curves is that it might allow us to make educated statistical comparisons once we have data from LL patients (of course with the caveat of a much-reduced number "at risk" in our case.)
Can't wait for us to start our trial and see the results!!!.
(18)
(0)